Levetiracetam Clonmel (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This binding modulates calcium‑dependent exocytosis, stabilising neuronal firing and lowering the likelihood of the abnormal electrical discharges that cause seizures.

The appropriate dose is individualized by the prescribing clinician based on factors such as the patient’s age, weight, renal function, seizure type and response to therapy. No fixed regimen is provided here; dosing decisions are made by a qualified healthcare professional.

Levetiracetam is classified as pregnancy category B1, indicating no evidence of fetal risk in animal studies but limited human data. It may be used during pregnancy only when the potential benefit justifies the risk. Limited data suggest it is excreted in breast milk; breastfeeding decisions should be made with a physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Levetiracetam offers a broad‑spectrum effect with minimal enzyme‑inducing properties, reducing the likelihood of drug‑drug interactions compared with many older antiepileptics such as carbamazepine or phenytoin. Its rapid absorption and linear pharmacokinetics make dosing predictable, though clinicians may still consider individual patient factors when selecting therapy.

Store Levetiracetam tablets at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep out of reach of children and avoid exposing the product to excessive heat or humidity.

Levetiracetam is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food. The exact timing and frequency are determined by the prescriber to maintain consistent blood levels and optimal seizure control.

Serious risks include severe allergic reactions (rash, swelling, breathing difficulty), psychiatric disturbances such as new‑onset depression, suicidal thoughts or psychosis, and rare blood disorders like neutropenia. Patients should seek immediate medical attention if any of these symptoms occur.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric illness, or those who cannot safely taper off the medication under medical supervision.